AssayIndex
Growth-hormone axis peptides

Ipamorelin

NNC 26-0161 · C38H49N9O5 · monoisotopic 711.3856 Da. The index holds 223 assay reports on this compound across 41 batches from 17 suppliers.

223 reports41 batchesmedian 99.48 %index spec 99.0 %
Section 1

Analytical fingerprint

Hand-authored chemistry. These properties describe the substance and do not change when a record is added.

A pentapeptide with two aromatic residues and an Aib. Purity is routinely 99 %+ and the compound is one of the index's system-suitability references for short-peptide work. The informative measurement is Trp oxidation, which tracks light exposure during shipping: lots shipped in clear glass show a mean sulfoxide-equivalent 0.4 pp higher than amber-glass lots across the index's ipamorelin set, one of the few shipping-condition effects here that reaches significance at the available n.

Molecular formula
C38H49N9O5
Monoisotopic mass
711.3856Da
Average mass
711.85Da
Residues
5
Nominal retention (RG-2, 30 min)
8.24min
Retention window
0.25min
Counter-ion as usually shipped
acetate
Typical label claims
2 mg · 5 mg · 10 mg
Analytical difficulty (index scale)
0.80 — straightforward
Purity is a defined quantity
YES
Section 2

Representative chromatogram

Drawn from this page's own medians. Not a scan, not an illustration, and not any single report.

032606520978113041 Ipamorelin8.24 min · 99.48 % 7.90 same trace · ×200 vertical expansion, baseline-corrected · main peak off-scale reporting threshold 0.05 % area 05101520253035 Retention time (min) Response (mAU)
Figure 1. A representative Ipamorelin trace on the index reference method RG-2, constructed from this page's own numbers: the main peak carries the index median purity of 99.48 % area at the nominal retention time of 8.24 min, and each impurity peak carries the median area the index has observed for that named species at its characteristic retention offset. It is not a scan of any single report — every individual record's own chromatogram is on its own page. The lower panel is the same trace at a stated vertical expansion, baseline-corrected, so the impurities are visible; the main peak runs off-scale there by design. Baseline noise is seeded from the compound slug.
Section 3

What the index has observed

Arithmetic over the 223 records the index holds. Aggregates on this page are computed over the records the index holds, which are not a random sample of the material on the market. Lots that get tested are lots someone chose to test. Read every figure here as a description of this dataset rather than as an estimate of a population.

Median purity 99.48% n=223
Interquartile range 0.97pp n=223
Minimum 97.34% n=223
Maximum 99.93% n=223
Pass rate vs spec 73.1% n=223
Median recovery vs claim 98.9% n=135
Median water 4.66% n=223
Median |mass error| 2.7ppm n=187
024487292.093.094.095.096.097.098.099.0100.092.00–92.25 %: n=092.25–92.50 %: n=092.50–92.75 %: n=092.75–93.00 %: n=093.00–93.25 %: n=093.25–93.50 %: n=093.50–93.75 %: n=093.75–94.00 %: n=094.00–94.25 %: n=094.25–94.50 %: n=094.50–94.75 %: n=094.75–95.00 %: n=095.00–95.25 %: n=095.25–95.50 %: n=095.50–95.75 %: n=095.75–96.00 %: n=096.00–96.25 %: n=096.25–96.50 %: n=096.50–96.75 %: n=096.75–97.00 %: n=097.00–97.25 %: n=097.25–97.50 %: n=197.50–97.75 %: n=597.75–98.00 %: n=898.00–98.25 %: n=1198.25–98.50 %: n=598.50–98.75 %: n=1298.75–99.00 %: n=1899.00–99.25 %: n=2499.25–99.50 %: n=2899.50–99.75 %: n=2899.75–100.00 %: n=83median 99.48 Purity (% area) Reports
Figure 2. Purity distribution across all 223 Ipamorelin records. Dashed line is this compound's median (99.48 %); the solid vertical is the index acceptance specification for the growth-hormone axis peptides class (99.0 %). Domain is fixed at 92–100 % on every purity histogram on this site so that compounds can be compared by eye — a wide distribution here is a hard compound, a narrow one is an easy one, and neither is a statement about the suppliers.
Section 4

By supplier

Suppliers with fewer than two purity records on this compound are omitted from the figure rather than drawn as a line. The full table, including the thin cells, is on the by-supplier page.

97.197.698.198.699.199.6100.1KPKP: Q1 98.53, median 99.06, Q3 99.60, n=20n=20QYBQYB: Q1 99.90, median 99.93, Q3 99.93, n=19outlier 98.62outlier 99.66outlier 99.72outlier 99.74n=19WWBWWB: Q1 99.69, median 99.93, Q3 99.93, n=19outlier 98.94outlier 99.14n=19FGPFGP: Q1 99.34, median 99.90, Q3 99.93, n=18n=18TFCTFC: Q1 99.06, median 99.24, Q3 99.93, n=16n=16QSCQSC: Q1 99.48, median 99.75, Q3 99.93, n=16n=16HJHJ: Q1 99.05, median 99.47, Q3 99.72, n=15n=15SSASSA: Q1 97.94, median 98.23, Q3 98.73, n=15n=15ERPERP: Q1 99.20, median 99.93, Q3 99.93, n=15n=15CPCCPC: Q1 97.87, median 98.10, Q3 98.80, n=14n=14HomopeptideHomopeptide: Q1 99.36, median 99.53, Q3 99.79, n=12n=12GGPepsGGPeps: Q1 99.11, median 99.41, Q3 99.72, n=12n=12SWBSWB: Q1 99.47, median 99.85, Q3 99.91, n=12n=12WXTWXT: Q1 97.90, median 98.00, Q3 98.14, n=8outlier 99.10n=8MKMMKM: Q1 98.77, median 98.82, Q3 99.06, n=8outlier 99.53n=8BCHBCH: Q1 99.28, median 99.35, Q3 99.42, n=2n=2SGNSGN: Q1 98.99, median 99.11, Q3 99.23, n=2n=2 Purity (% area)
Figure 3. Ipamorelin purity by supplier, ordered by coverage. The vertical line is the index acceptance specification. Boxes that overlap are suppliers this dataset cannot separate, and most of them overlap.

Full per-supplier table with n= caveats →

Section 5

Characteristic impurities and degradants

The left three columns are authored chemistry — what this molecule characteristically carries and where it elutes. The right three are what the index has actually reported.

Named speciesΔRT (min, RG-2)Δ mass (Da)Seen inMedian % areaMax % area
des-Lys (−128 Da)-0.22-128.09591%0.061.58
oxidised Trp (+16 Da)-0.34+15.99578%0.121.37
C-terminal free acid (+1 Da)+0.18+0.98476%0.071.16
[D-Trp]-epimer-0.12mass-identical70%0.061.42
Aib-deletion sequence (−85 Da)-0.28-85.05365%0.081.49

Degradation pathways

  • Trp oxidation on light exposure
  • C-terminal amide hydrolysis

Full impurity profile, with what each named species implies about the synthesis →

Section 7

Quarterly coverage

QuarterReportsMedian purityRange
2024-Q10n<3—
2024-Q20n<3—
2024-Q33899.4797.61–99.93
2024-Q42399.5597.87–99.93
2025-Q12598.9997.34–99.93
2025-Q22399.4598.60–99.93
2025-Q32299.3198.56–99.93
2025-Q41899.0597.73–99.93
2026-Q12999.5398.31–99.93
2026-Q22299.9398.77–99.93
2026-Q32399.4498.18–99.93

Quarter-by-quarter detail →

Section 8

Most recent records

The 25 most recent Ipamorelin records of 223.
ReportSupplierLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-042181HomopeptideHOMO-2608-A9045Janoshik2026-Q399.784.79—Supplier-supplied1MARGINAL
AX-2026-042180HomopeptideHOMO-2608-A9045Janoshik2026-Q399.394.74105.5Supplier-supplied1MARGINAL
AX-2026-042184HomopeptideHOMO-2608-A9045Kestrel2026-Q399.274.79103.2Supplier-supplied1MARGINAL
AX-2026-041427QYBQYB-2605-H4298Janoshik2026-Q399.934.12—Supplier-supplied0PASS
AX-2026-042183HomopeptideHOMO-2608-A9045VendorInvestigate2026-Q399.384.97—Buyer-sourced1MARGINAL
AX-2026-043090KPKP-2606-D5887Janoshik2026-Q398.183.07101.2Laboratory-retained1FAIL
AX-2026-042191HomopeptideHOMO-2608-A9045Medutest2026-Q399.675.00104.6Supplier-supplied1MARGINAL
AX-2026-041425QYBQYB-2605-H4298Janoshik2026-Q399.933.6593.4Supplier-supplied0PASS
AX-2026-042185HomopeptideHOMO-2608-A9045Nordanalyt2026-Q399.264.6395.0Supplier-supplied1MARGINAL
AX-2026-043086KPKP-2606-D5887PeptideMeter2026-Q398.743.4591.6Supplier-supplied1FAIL
AX-2026-043088KPKP-2606-D5887VendorInvestigate2026-Q398.283.4491.0Buyer-sourced1FAIL
AX-2026-042189HomopeptideHOMO-2608-A9045Janoshik2026-Q399.635.00102.4Supplier-supplied1MARGINAL
AX-2026-042186HomopeptideHOMO-2608-A9045Medutest2026-Q399.444.68—Supplier-supplied1MARGINAL
AX-2026-043087KPKP-2606-D5887Janoshik2026-Q398.213.5188.9Supplier-supplied2FAIL
AX-2026-042187HomopeptideHOMO-2608-A9045Janoshik2026-Q399.304.83—Buyer-sourced1MARGINAL
AX-2026-043091KPKP-2606-D5887Janoshik2026-Q398.483.94102.7Supplier-supplied1FAIL
AX-2026-042190HomopeptideHOMO-2608-A9045Medutest2026-Q399.935.1892.0Supplier-supplied0PASS
AX-2026-042182HomopeptideHOMO-2608-A9045Kestrel2026-Q399.934.6691.5Supplier-supplied1MARGINAL
AX-2026-043089KPKP-2606-D5887Medutest2026-Q399.073.6789.4Supplier-supplied2MARGINAL
AX-2026-041424QYBQYB-2605-H4298Janoshik2026-Q399.934.26101.0Supplier-supplied1MARGINAL
AX-2026-042188HomopeptideHOMO-2608-A9045Janoshik2026-Q399.824.68—Supplier-supplied0PASS
AX-2026-041426QYBQYB-2605-H4298Nordanalyt2026-Q399.934.25—Supplier-supplied1MARGINAL
AX-2026-041428QYBQYB-2605-H4298Janoshik2026-Q399.933.85106.9Supplier-supplied2FAIL
AX-2026-042026TFCTFC-2603-M6766Janoshik2026-Q299.934.8591.9Supplier-supplied0PASS
AX-2026-041309WWBWWB-2604-E3153Janoshik2026-Q299.936.14—Supplier-supplied0PASS